Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with or without epoetin beta in ESA-resistant lower-risk myelodysplastic syndromes without chromosome 5 abnormality
2008-008262-12Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Sep 2009
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide and epoetin beta in myelodysplastic syndrome (MDS) (2 arms), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Primary efficacy endpoint and Erythroid response rate after 4 courses. Started Sep 2009; status: completed.
02
Drugs
lenalidomideepoetin beta
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-008262-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008262-12.